Anti-inflammatory loaded poly-lactic glycolic acid nanoparticle formulations to enhance myocardial gene transfer: an in-vitro assessment of a drug/gene combination therapeutic approach for direct injection

Abstract

BackgroundCardiac gene therapy for heart disease is a major translational research area with potential, yet problems with safe and efficient gene transfer into cardiac muscle remain unresolved. Existing methodology to increase vector uptake include modifying the viral vector, non-viral particle encapsulation and or delivery with device systems. These advanced methods have made improvements, however fail to address the key problem of inflammation in the myocardium, which is known to reduce vector uptake and contribute to immunogenic adverse events. Here we propose an alternative method to co-deliver anti-inflammatory drugs in a controlled release polymer with gene product to improve therapeutic effects.MethodsA robust, double emulsion production process was developed to encapsulate drugs into nanoparticles. Briefly in this proof of concept study, aspirin and prednisolone anti-inflammatory drugs were encapsulated in various poly-lactic glycolic acid polymer (PLGA) formulations. The resultant particle systems were characterized, co-delivered with GFP plasmid, and evaluated in harvested myocytes in culture for uptake.ResultsHigh quality nanoparticles were harvested from multiple production runs, with an average 64 ± 10 mg yield. Four distinct particle drug system combinations were characterized and evaluated in vitro: PLGA(50:50) Aspirin, PLGA(65:35) Prednisolone, PLGA(65:35) Aspirin and PLGA(50:50) Prednisolone Particles consisted of spherical shape with a narrow size distribution 265 ± 104 nm as found in scanning electron microscopy imaging. Prednisolone particles regardless of PLGA type were found on average ≈ 100 nm smaller than the aspirin types. All four groups demonstrated high zeta potential stability and re-constitution testing prior to in vitro. In vitro results demonstrated co uptake of GFP plasmid (green) and drug loaded particles (red) in culture with no incidence of toxicity.ConclusionsNano formulated anti-inflammatories in combination with standalone gene product therapy may offer a clinical solution to maximize cardiac gene therapy product effects while minimizing the risk of the host response in the inflammatory myocardial environment.

Using Micro- and Macro-Level Network Metrics Unveils Top Communicative Gene Modules in Psoriasis

“…Subsequent large-scale validation of the latter in serum is critical in order to prove these proteins as putative biomarkers or/and therapeutic targets for the diagnosis and/or the treatment of psoriasis. Beyond this, since there are several experimental studies in which combinatorial gene sets have been used as therapeutic/diagnostic targets [51,52], from a network science point of view, leading to our intra-and inter-module interactions asserted by experimental studies, it is likely that the mentioned top communicative subnetworks will unveil disease-specific patterns.…”

Decorin-loaded poly lactic-co-glycolic acid nanoparticles modified by anti-alpha fetoprotein antibody: preparation, proliferation inhibition and induced apoptosis effects on HepG2 cells in vitro

“…Regulating the expression of apoptosis‐related proteins can induce apoptosis. It has been proved that upregulating the expression of proteins such as caspase‐3 and caspase‐9 genes or downregulating the expression of proteins such as Bcl‐2 and Mcl‐1 genes can promote tumour cell apoptosis . Bcl‐2 gene is a member of Bcl‐2 family and a kind of an anti‐apoptotic factor.…”

The Potential for Nanotechnology to Improve Delivery of Therapy to the Acute Ischemic Heart

“…Furthermore, the treatment of cells with nanoparticle-encapsulated anti-inflammatory drugs may improve transfection for gene therapy that could be used for later myocardial repair. [51] Recent work shows that macrophage polarization is an important consideration in myocardial injury. An adenosine 2B receptor agonist [52], cellular postconditioning [47], and silencing of interferon regulatory factor 5 in macrophages [53] have all been linked to a shift away from a proinflammatory M1-like macrophage phenotype in models of myocardial ischemia with a corresponding improvement in injury outcome.…”